Arming Immune Cells for Battle: A Brief Journey through the Advancements of T and NK Cell Immunotherapy
The promising development of adoptive immunotherapy over the last four decades has revealed numerous therapeutic approaches in which dedicated immune cells are modified and administered to eliminate malignant cells. Starting in the early 1980s, lymphokine activated killer (LAK) cells were the first...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-03-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/6/1481 |
| _version_ | 1797540319910166528 |
|---|---|
| author | Philipp Wendel Lisa Marie Reindl Tobias Bexte Leander Künnemeyer Vinzenz Särchen Nawid Albinger Andreas Mackensen Eva Rettinger Tobias Bopp Evelyn Ullrich |
| author_facet | Philipp Wendel Lisa Marie Reindl Tobias Bexte Leander Künnemeyer Vinzenz Särchen Nawid Albinger Andreas Mackensen Eva Rettinger Tobias Bopp Evelyn Ullrich |
| author_sort | Philipp Wendel |
| collection | DOAJ |
| description | The promising development of adoptive immunotherapy over the last four decades has revealed numerous therapeutic approaches in which dedicated immune cells are modified and administered to eliminate malignant cells. Starting in the early 1980s, lymphokine activated killer (LAK) cells were the first ex vivo generated NK cell-enriched products utilized for adoptive immunotherapy. Over the past decades, various immunotherapies have been developed, including cytokine-induced killer (CIK) cells, as a peripheral blood mononuclear cells (PBMCs)-based therapeutic product, the adoptive transfer of specific T and NK cell products, and the NK cell line NK-92. In addition to allogeneic NK cells, NK-92 cell products represent a possible “off-the-shelf” therapeutic concept. Recent approaches have successfully enhanced the specificity and cytotoxicity of T, NK, CIK or NK-92 cells towards tumor-specific or associated target antigens generated by genetic engineering of the immune cells, e.g., to express a chimeric antigen receptor (CAR). Here, we will look into the history and recent developments of T and NK cell-based immunotherapy. |
| first_indexed | 2024-03-10T12:58:28Z |
| format | Article |
| id | doaj.art-d50208623c3c4fffa4f8964b35209b8a |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T12:58:28Z |
| publishDate | 2021-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-d50208623c3c4fffa4f8964b35209b8a2023-11-21T11:42:30ZengMDPI AGCancers2072-66942021-03-01136148110.3390/cancers13061481Arming Immune Cells for Battle: A Brief Journey through the Advancements of T and NK Cell ImmunotherapyPhilipp Wendel0Lisa Marie Reindl1Tobias Bexte2Leander Künnemeyer3Vinzenz Särchen4Nawid Albinger5Andreas Mackensen6Eva Rettinger7Tobias Bopp8Evelyn Ullrich9Children’s Hospital, Division for Stem Cell Transplantation, Immunology and Intensive Care Medicine, Goethe-University Frankfurt, 60590 Frankfurt am Main, GermanyChildren’s Hospital, Division for Stem Cell Transplantation, Immunology and Intensive Care Medicine, Goethe-University Frankfurt, 60590 Frankfurt am Main, GermanyChildren’s Hospital, Division for Stem Cell Transplantation, Immunology and Intensive Care Medicine, Goethe-University Frankfurt, 60590 Frankfurt am Main, GermanyChildren’s Hospital, Division for Stem Cell Transplantation, Immunology and Intensive Care Medicine, Goethe-University Frankfurt, 60590 Frankfurt am Main, GermanyInstitute for Experimental Cancer Research in Pediatrics, Goethe-University Frankfurt, 60528 Frankfurt am Main, GermanyChildren’s Hospital, Division for Stem Cell Transplantation, Immunology and Intensive Care Medicine, Goethe-University Frankfurt, 60590 Frankfurt am Main, GermanyDepartment of Medicine 5, University Hospital Erlangen, University of Erlangen-Nuremberg, 91054 Erlangen, GermanyChildren’s Hospital, Division for Stem Cell Transplantation, Immunology and Intensive Care Medicine, Goethe-University Frankfurt, 60590 Frankfurt am Main, GermanyInstitute for Immunology, University Medical Center, Johannes Gutenberg-University Mainz, 55131 Mainz, GermanyChildren’s Hospital, Division for Stem Cell Transplantation, Immunology and Intensive Care Medicine, Goethe-University Frankfurt, 60590 Frankfurt am Main, GermanyThe promising development of adoptive immunotherapy over the last four decades has revealed numerous therapeutic approaches in which dedicated immune cells are modified and administered to eliminate malignant cells. Starting in the early 1980s, lymphokine activated killer (LAK) cells were the first ex vivo generated NK cell-enriched products utilized for adoptive immunotherapy. Over the past decades, various immunotherapies have been developed, including cytokine-induced killer (CIK) cells, as a peripheral blood mononuclear cells (PBMCs)-based therapeutic product, the adoptive transfer of specific T and NK cell products, and the NK cell line NK-92. In addition to allogeneic NK cells, NK-92 cell products represent a possible “off-the-shelf” therapeutic concept. Recent approaches have successfully enhanced the specificity and cytotoxicity of T, NK, CIK or NK-92 cells towards tumor-specific or associated target antigens generated by genetic engineering of the immune cells, e.g., to express a chimeric antigen receptor (CAR). Here, we will look into the history and recent developments of T and NK cell-based immunotherapy.https://www.mdpi.com/2072-6694/13/6/1481NK cellT cellCIK cellNK-92cell therapyimmune therapy |
| spellingShingle | Philipp Wendel Lisa Marie Reindl Tobias Bexte Leander Künnemeyer Vinzenz Särchen Nawid Albinger Andreas Mackensen Eva Rettinger Tobias Bopp Evelyn Ullrich Arming Immune Cells for Battle: A Brief Journey through the Advancements of T and NK Cell Immunotherapy Cancers NK cell T cell CIK cell NK-92 cell therapy immune therapy |
| title | Arming Immune Cells for Battle: A Brief Journey through the Advancements of T and NK Cell Immunotherapy |
| title_full | Arming Immune Cells for Battle: A Brief Journey through the Advancements of T and NK Cell Immunotherapy |
| title_fullStr | Arming Immune Cells for Battle: A Brief Journey through the Advancements of T and NK Cell Immunotherapy |
| title_full_unstemmed | Arming Immune Cells for Battle: A Brief Journey through the Advancements of T and NK Cell Immunotherapy |
| title_short | Arming Immune Cells for Battle: A Brief Journey through the Advancements of T and NK Cell Immunotherapy |
| title_sort | arming immune cells for battle a brief journey through the advancements of t and nk cell immunotherapy |
| topic | NK cell T cell CIK cell NK-92 cell therapy immune therapy |
| url | https://www.mdpi.com/2072-6694/13/6/1481 |
| work_keys_str_mv | AT philippwendel armingimmunecellsforbattleabriefjourneythroughtheadvancementsoftandnkcellimmunotherapy AT lisamariereindl armingimmunecellsforbattleabriefjourneythroughtheadvancementsoftandnkcellimmunotherapy AT tobiasbexte armingimmunecellsforbattleabriefjourneythroughtheadvancementsoftandnkcellimmunotherapy AT leanderkunnemeyer armingimmunecellsforbattleabriefjourneythroughtheadvancementsoftandnkcellimmunotherapy AT vinzenzsarchen armingimmunecellsforbattleabriefjourneythroughtheadvancementsoftandnkcellimmunotherapy AT nawidalbinger armingimmunecellsforbattleabriefjourneythroughtheadvancementsoftandnkcellimmunotherapy AT andreasmackensen armingimmunecellsforbattleabriefjourneythroughtheadvancementsoftandnkcellimmunotherapy AT evarettinger armingimmunecellsforbattleabriefjourneythroughtheadvancementsoftandnkcellimmunotherapy AT tobiasbopp armingimmunecellsforbattleabriefjourneythroughtheadvancementsoftandnkcellimmunotherapy AT evelynullrich armingimmunecellsforbattleabriefjourneythroughtheadvancementsoftandnkcellimmunotherapy |